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Brain phosphorylation of MeCP2 
at serine 164 is developmentally 
regulated and globally alters its 
chromatin association
Gilda Stefanelli1, Anna Gandaglia1, Mario Costa2, Manjinder S. Cheema3, Daniele Di Marino4, 
Isabella Barbiero5, Charlotte Kilstrup-Nielsen5, Juan Ausió3 & Nicoletta Landsberger1,6
MeCP2 is a transcriptional regulator whose functional alterations are responsible for several autism 
spectrum and mental disorders. Post-translational modifications (PTMs), and particularly differential 
phosphorylation, modulate MeCP2 function in response to diverse stimuli. Understanding the 
detailed role of MeCP2 phosphorylation is thus instrumental to ascertain how MeCP2 integrates the 
environmental signals and directs its adaptive transcriptional responses. The evolutionarily conserved 
serine 164 (S164) was found phosphorylated in rodent brain but its functional role has remained 
uncharacterized. We show here that phosphorylation of S164 in brain is dynamically regulated during 
neuronal maturation. S164 phosphorylation highly impairs MeCP2 binding to DNA in vitro and largely 
affects its nucleosome binding and chromatin affinity in vivo. Strikingly, the chromatin-binding 
properties of the global MeCP2 appear also extensively altered during the course of brain maturation. 
Functional assays reveal that proper temporal regulation of S164 phosphorylation controls the ability of 
MeCP2 to regulate neuronal morphology. Altogether, our results support the hypothesis of a complex 
PTM-mediated functional regulation of MeCP2 potentially involving a still poorly characterized 
epigenetic code. Furthermore, they demonstrate the relevance of the Intervening Domain of MeCP2 for 
binding to DNA.
Epigenetics plays a fundamental role in the development and function of the mammalian nervous system. By 
linking DNA methylation to chromatin structure, the methyl-binding protein MeCP2 appears as a key player in 
reading the information encoded by methylated cytosines. Accordingly, the X linked MECP2 gene is associated 
with several neurological disorders, of which Rett syndrome represents the most studied1.
MeCP2 was originally isolated as a ubiquitously expressed protein containing two main functional domains: 
a methyl-CpG binding domain (MBD) mediating the preferential binding of MeCP2 to methylated CpGs and a 
transcription repression domain (TRD) capable of repressing transcription through different molecular mech-
anisms, including the recruitment of histone deacetylase activities to methylated DNA2. As of today, MeCP2 
is subdivided into five main structural domains corresponding to an N-terminal domain (residues 1–78), the 
MBD (residues 79–162), the intervening domain (ID; residues 163–206), the TRD (residues 207–310) and the 
C-terminal domain (residues 311–486) [amino acid numbers refer to the human E2 isoform]. The functional 
relevance of all these domains, with the exception of the N-terminal domain, can be inferred by their frequent 
association with pathological missense mutations3. Furthermore, the ID and the TRD appear as the domains of 
MeCP2 that are most commonly involved in several and often labile protein/protein interactions3,4.
The structural complexity of MeCP2 fits well with its versatile functionality. In mature neurons, where MeCP2 
abundance corresponds roughly to one molecule every two nucleosomes, the protein can serve as an alternative 
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linker histone, organizing a specialized chromatin structure that dampens transcriptional noise5. MeCP2 can 
also activate gene transcription possibly through its interaction with CREB16. Additionally, MeCP2 has been 
proposed to directly affect splicing7,8, miRNA biogenesis9 and centrosomal functions10. Post-translational modifi-
cations (PTMs) of MeCP2 are likely to generate and regulate this functional versatility. Indeed, mass spectrometry 
analyses have identified several phosphorylation sites. In neurons, phosphorylation events occur under basal 
conditions and/or in response to neuronal activity11,12. The addition of a negatively charged phosphate group 
can dramatically impact protein functions. Consequently, MeCP2 phosphorylation might affect its sub-nuclear 
localization13. However, immunofluorescence studies performed with phospho-specific antibodies and/or gen-
erating specific phospho-defective mutants of MeCP2 failed in identifying an altered intracellular distribution 
of MeCP2. Further, we still lack insights into the molecular consequences of S421 and S80 phosphorylation of 
MeCP2, which represent the better-studied MeCP2 post-translational modifications. Of relevance, data obtained 
from primary neurons led to propose that the neuronal activity dependent phosphorylation of S421 induces the 
detachment of MeCP2 from specific promoters14. However, these results were challenged by a more recent in vivo 
study demonstrating that neuronal depolarization does not alter MeCP2 binding to several promoters. Moreover, 
the S421A phospho-defective derivative of MeCP2 shows a chromatin distribution that overlaps with that of the 
wild-type (WT) protein15. To conclude, no data have so far been able to demonstrate an effect of MeCP2 phospho-
rylation on its binding to target sequences or chromatin. In contrast, it has been demonstrated that Threonine 308 
(T308) phosphorylation interferes with the interaction of MeCP2 with the corepressor complex NCoR, therefore 
reducing its repressive activity16. Importantly, a phospho-defective Mecp2T308A/y knock in mouse line exhibits 
a large spectrum of neurological symptoms highly phenocopying several mouse models of Mecp2 disorders16. 
Additionally, it has been proved that MeCP2 phosphorylation impacts dendritic arborization, spine maturation 
and generally the development and function of the nervous system11,12. All these observations highlight the rel-
evance of studying the function and regulation of MeCP2 phosphorylation for advancing our comprehension of 
RTT and MECP2 related disorders; in particular, we have proposed to start focusing on sites that are evolutionally 
conserved and/or have been found mutated in patients12.
Most studies have so far focused on residues located within the MBD or the TRD. However, several were the 
rationales for studying phosphorylation of the ID. We have already proposed this protein region to be a frequent 
target of PTMs12. Indeed, out of 44 residues, 7 have been predicted to be subject of phosphorylation in human and 
experimental evidence is present for 3 (S164, S166 and S178) in mouse (Fig. 1a). K171 has been recently proved 
to be acetylated17, whereas the ID has been demonstrated as a major site of poly(ADP-rybosyl)ation18. Both these 
PTMs highly impact on MeCP2 functions: K171 acetylation modulates the interaction of MeCP2 with ATRX and 
HDAC1, while (ADP-rybosyl)ation reduces the capability of MeCP2 to cluster heterochromatin17,18. By analyzing 
evolutional conservation, we noticed that S164 and S166 have been maintained from X. laevis to humans (Fig. 1a). 
Although none of these sites has been found mutated in MECP2-related disorders, S164 and S166 are proximal 
to a region of the methyl binding domain that is often mutated in patients; furthermore, a close by pathological 
mutation, R167W, has recently been linked to intellectual disability and autism in males (see Fig. 1a19). S164 is 
particularly interesting since it has been found modified in neuronal tissues; in fact, its phosphorylation was iden-
tified by mass spectrometry analysis of immuno precipitated MeCP2 from normal and epileptic rodent brains20. 
Considering all above, we decided to characterize this PTM of MeCP2.
Our studies demonstrate that S164 phosphorylation is the first post-translational modification of MeCP2 that 
globally affects its sub-nuclear localization and chromatin affinity. In neurons S164 phosphorylation is high in 
abundance and developmentally regulated; importantly, its proper regulation appears to be necessary for neu-
ronal maturation. The study of this phosphorylation event allowed revealing that MeCP2 dramatically changes its 
affinity for chromatin along brain maturation.
Results
In brain phosphorylation of Mecp2 at S164 is developmentally modulated. To study S164 phos-
phorylation we raised a polyclonal phospho-site-specific antibody (anti P-S164). Western blotting of WT and 
Mecp2-null brain lysates clearly indicates that the anti P-S164 specifically recognizes Mecp2 in a phosphorylation 
dependent manner (Fig. 1b). We also tested HEK293T cell lysates expressing exogenous GFP-tagged WT MeCP2 
or its phospho-defective (S164A) or phospho-mimetic (S164D) derivatives; although all derivatives of MeCP2 are 
efficiently expressed, the anti P-S164 antibody fails to recognize both mutant versions of MeCP2 (Fig. 1c). These 
results demonstrate that the anti P-S164 antibody specifically recognizes the S164 phospho-isoform of MeCP2.
By investigating the distribution of P-S164 Mecp2 in adult mouse tissues, we found that, despite some expres-
sion in non neuronal tissues, P-S164 Mecp2 is abundant in brain (Fig. 2a).
Although several studies, including ours presented in Fig. 2b, indicate that MeCP2 phosphorylation is often 
regulated in different brain regions, almost no information is so far available regarding the regulation of these 
post-translational modifications during brain development. To understand whether S164 phosphorylation is 
constitutively or dynamically expressed, we compared its levels in the maturing mouse brain with those of total 
Mecp2. Remarkably, P-S164 Mecp2 is low in abundance at P0, peaks around P4, and gradually decreases at later 
stages of development (Fig. 2c). Similarly to the maturing brain, the expression of P-S164 Mecp2 is regulated also 
during neuronal differentiation in vitro, reaching a peak after 7–9 days of culture and dramatically diminishing 
with maturation (Fig. 2d). The peculiar expression profile of P-S164 Mecp2 expression evokes its possible involve-
ment in post-natal neuronal maturation.
Thus, to the best of our knowledge, this is the first report of a phospho-isoform of Mecp2 that is developmen-
tally regulated in brain.
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S164 phosphorylation impairs the affinity of MeCP2 for DNA independently on the methyla-
tion status. Two complementary approaches were used to reveal whether S164 phosphorylation generally 
affects Mecp2 binding to chromatin/heterochromatin and, consequently, its sub-nuclear distribution.
Based on the accumulation of Mecp2 at the highly methylated mouse pericentromeric heterochromatin, 
we first used epifluorescence microscopy to compare the sub-nuclear localization of the exogenously expressed 
GFP-MeCP2 WT, S164A and S164D derivatives (Fig. 3). The MeCP2 R106W RTT mutant was included in this 
assay because of its inability to bind methylated DNA and to accumulate on heterochromatic foci21,22. NIH3T3 
mouse fibroblasts (Fig. 3a) and Mecp2-null mouse embryonic fibroblasts (MEFs; Fig. 3b), which offer the obvious 
advantage of not expressing any competing endogenous Mecp2, were used as cell models. The heterochromatic 
accumulation of the different GFP-fusion proteins was measured as the ratio of the mean intensity of chromo-
centers versus nucleoplasm (Fig. 3; right panels). Perfectly matching results were obtained with both cell lines. 
Indeed, WT GFP-MeCP2 colocalizes with the DAPI-positive heterochromatic foci, whereas the R106W mutant 
shows a largely diffuse localization. Remarkably, the distribution of the phospho-mimetic S164D derivative 
resembles that of the R106 W mutant by having an increased intensity outside the chromocenters. Accordingly, 
a statistically significant reduction in the chromocenter accumulation was measured. As further indication that 
S164 phosphorylation reduces the affinity of Mecp2 for methylated heterochromatin we observed that the S164A 
phospho-defective derivative, even if resembling WT MeCP2, shows a significantly increased accumulation at 
heterochromatic foci in both cell types.
Figure 1. Development of an MeCP2 S164 phospho-specific antibody. (a) (Adapted from16) Schematic 
illustration showing the localization of frequent pathogenic missense mutations within MeCP2 domains. The 
recently identified R167 W pathogenic mutation is indicated in red. Lower part shows alignment of the ID (aa 
163–206) from H. sapiens to X. laevis. Box shows the conserved S164. Red residues represent experimentally 
determined phosphorylated sites; in green are indicated phosphorylated amino acids predicted by GPs 2.0 
and NetPhos 2.012. (b) Total brain lysates were prepared from adult WT and KO mice, treated or not with 
λ phosphatase and analyzed by WB using antibodies against MeCP2 and P-S164 MeCP2. 30 μ g of extract 
were loaded in each lane. Neuronal specific β III tubulin (Tuj1) was used as loading control. (c) Extracts 
from HEK293T cells expressing GFP-MeCP2 or its S164A and S164D derivatives were analyzed by WB with 
antibodies against P-S164 MeCP2 or total MeCP2. 20 μ g of total lysates were loaded in each lane. Tubulin was 
used as loading control.
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Few groups, including ours, have used fluorescence recovery after photobleaching (FRAP) to study 
chromatin-binding kinetics of MeCP2 in vivo21,23,24. All reports demonstrated that MeCP2 is a mobile protein 
that, although tightly bound to chromatin, continuously exchanges with the nucleoplasm. A fraction of the pro-
tein, however, is irreversibly bound to chromatin. Furthermore, by comparing the recovery of fluorescence at 
chromocenters with respect to the outside of the heterochromatic foci (nucleoplasm), it has been established that 
MeCP2 binding is stronger and less reversible in the areas of higher methylation21. Similarly, we tested the mobil-
ity and chromatin binding of WT GFP-MeCP2 or its phospho-defective and –mimetic derivatives in NIH3T3 
cells. Bleaching was performed for 300 milliseconds along a strip (strip-FRAP) covering simultaneously both 
chromocenter and nucleoplasm regions. A representative recovery of fluorescence after photobleaching for both 
chromatin fractions of GFP-MeCP2 WT, phosho-mimetic S164D and phospho-defective S164A is indicated in 
Figure 2. In brain phosphorylation of MeCP2 at S164 is abundant and developmentally regulated. (a,b) 
60 μ g of total brain and tissue lysates (a) and 30 μ g of total brain or brain area lysates (b) were subjected to 
WB and incubated with antibodies specific to P-S164 MeCP2 or total MeCP2. (c) Brains at different ages 
were lysed and probed with antibodies against MeCP2 and P-S164 MeCP2. Tubulin was used as loading 
control. The graph represents the ratio between P-S164 MeCP2 and total MeCP2 and was obtained by 
integrating three independent experiments (mean ± S.E.M * p = < 0.05, * * p = < 0.01, * * * p = < 0.001, one way 
ANOVA). (d) Lysates of primary hippocampal neurons at the indicated days in vitro (DIV) were probed with 
antibodies against MeCP2 or P-S164 MeCP2. Tuj1 was used as loading control. The graph represents the ratio 
between P-S164 MeCP2 and total MeCP2 and was obtained by integrating three independent experiments 
(mean ± S.E.M * p = < 0.05, * * p = < 0.01, * * * p = < 0.001, one way ANOVA).
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Fig. 4a. We consistently found that WT GFP-MeCP2 shows a stronger binding to heterochromatin (left panels) 
with a concomitantly ampler immobile fraction than to euchromatin (the nucleoplasmic fraction; right panels). 
In accordance with Fig. 3, our live-cell kinetic data indicate that the phospho-mimetic S164D derivative inter-
acts only very transiently and with low affinity with both chromatin fractions, whereas the phospho-defective 
S164A derivative shows the opposite trend and has an overall stronger affinity for chromatin. In fact, the 
phospho-defective MeCP2 isoform exhibits a statistically significant increase in both the recovery time and 
amplitude of the immobile fraction.
To obtain molecular insights regarding the above results, we have modeled the structure of the last portion 
of the crystal structure of the human MBD-ID (aa 163–170) complexed with a methylated BDNF sequence25 
(Fig. 5a); S164 phosphorylation has also been modeled (Fig. 5b). The C-terminal region of the MBD is 
Figure 3. MeCP2 phosphorylation at S164 affects the accumulation at heterochromatic foci. (a,b) 
Representative images from NIH3T3 (a) and Mecp2-null mouse embryonic fibroblasts (MEF) (b) transfected 
with GFP-MeCP2 WT or its S164A and S164D derivatives. Immunofluorescence was performed using 
antibodies against GFP and DAPI. The DNA binding-defective R106W mutant was used as control. Graphs 
show the ratio between fluorescence at chromocenters and at nucleoplasm (mean ± S.E.M). Each dot represents 
a single cell. Black dots highlight the representative cells shown in each panel. (NIH3T3 WT n = 41, S164A 
n = 53, S164D n = 101) (MEF WT n = 46, S164A n = 49, S164D n = 50). (* p = < 0.05, * * p = < 0.01,  
* * * p = < 0.001, * * * * p = < 0.0001, one way ANOVA).
www.nature.com/scientificreports/
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characterized by the presence of two structural motifs, Asx and ST25. The Asx motif (156DFT158) forms a turn 
stabilized by a hydrogen bond between the main chain of T158 and the side chain of D156 (Fig. 5a). The ST motif 
(158TVTG161) stabilizes the hydrogen bonds established by the hydroxyl group of T158 with the surrounding 
residues; this region directly contacts the DNA through V159 (Fig. 5a). Of note, R106 is a key residue for the 
interaction with DNA25 and the orientation of its side chain is stabilized by the peculiar structural arrangement 
of the Asx and ST motifs25.
The three-dimensional models reported in Fig. 5a,b. in the absence and presence of S164 phosphoryla-
tion respectively, have been subjected to structure regularization through an energy minimization process. 
Importantly, S164 phosphorylation leads to a rearrangement of the side chains of the residues belonging to the 
Asx and ST motifs (Fig. 5b). Upon phosphorylation, the side chain of R162, which is important for the stabiliza-
tion of the interaction between D156 and T158 (Fig. 5a), changes its orientation, and establishes an electrostatic 
interaction with the phosphate group bound to S164 (Fig. 5b), therefore modifying the structure of the Asx and 
ST motifs. Figure 5c,d report the electrostatic potential mapped on the surface of the models after energy minimi-
zation. The electrostatic potential of the region surrounding the phosphorylation is more negative with respect to 
the same region without the modification, thus altering the distribution of the charges in the C-terminal portion 
of the MBD. This increased negative charge on the protein surface in contact with DNA could cause a repulsive 
effect with the negatively charged DNA backbone, therefore decreasing the interaction strength between the two 
macromolecules.
The validity of these structural predictions has been tested analyzing by electrophoretic mobility assays 
(EMSA) the capacity of MeCP2 fragments (aa 74–172) to bind methylated (mCG; mCA) and unmethylated DNA 
probes that have already been used26. Of note, these polypeptides lack one of the two conserved high-mobility 
Figure 4. P-S164 MeCP2 shows a minor binding to chromatin. (a) Relative mobility of MeCP2 WT, S164A, 
and S164D in chromocenters (left panel) and nucleoplasm (right panel) of NIH3T3 cells. Representative 
quantification of the signal intensity: blue (S164D), red (S164A), black (WT). (b,c) Summary of average 
values for immobile fraction (b) and T1/2 (c) (mean ± S.E.M) measured at chromocenters (left panel) and 
nucleoplasm (right panel) in cells transfected with GFP-MeCP2 WT (black), S164A (red) and S164D (blue) 
derivatives (WT n = 7, S164A n = 9, S164D n = 8). (* p = < 0.05, * * p = < 0.01, * * * p = < 0.001,  
* * * * p = < 0.0001, one way ANOVA).
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group like AT-hook motifs of MeCP2 (aa 185–197) that, although still devoid of experimental significance, is 
considered a protein domain binding the minor groove of AT-rich DNA27. As shown in Fig. 5e, both the WT and 
S164A polypeptides show largely overlapping DNA binding properties, characterized by a subtle but consistently 
higher affinity for DNA methylated on CG. On the contrary, the S164D polypeptide produces a smeared signal, 
although showing a withdrawal of the free probe comparable to that of the WT peptide. This suggests that the 
phospho-protein, in accordance with the in silico reconstruction, dynamically binds and detaches from the probe; 
the absence of stable DNA/protein complexes limits the formation of discrete shifted bands.
P-S164 MeCP2 shows altered nucleosome binding. Our data suggest that by regulating the phos-
phorylation state of S164, cells modulate the global affinity of MeCP2 to chromatin and its distribution within 
the nucleus. We proceeded analyzing whether S164 phosphorylation might similarly affect Mecp2 binding to 
chromatin in vivo. Through salt extraction experiments, we compared P-S164 Mecp2 solubility with respect to 
that of total Mecp2. Histone H1 withdrawal was used as reference (Fig. 6a). We tested P4 and P30 mouse brains 
respectively representing high and low levels of P-S164 Mecp2 (Fig. 2c). As reported28,29, in mature brain (P30) 
Mecp2 shows a high affinity for chromatin, being mainly extracted between 500 and 700 mM NaCl. In accordance 
with previous results, P-S164 Mecp2 is more soluble; indeed, it is mainly extracted at 400 mM NaCl (Fig. 6a, upper 
panel). At P4, the increased solubility of the MeCP2 phospho-isoform is confirmed; strikingly, the solubility of 
total Mecp2 is dramatically increased and the majority of the protein is extracted at 400 mM NaCl as P-S164 
Mecp2 (Fig. 6a, lower panels). We confirmed these data performing salt extraction experiments with NIH3T3 
cells expressing GFP-MeCP2 or its phospho-mimetic/defective derivatives (Fig. 6b). Our results demonstrate that 
WT MeCP2 and its S164A derivative are less soluble than the S164D protein, confirming that the presence of a 
negative charge on S164 reduces MeCP2 affinity for chromatin.
The chromatin binding properties of Mecp2 probably depend on its affinity for nucleosomal and naked DNA. 
We used micrococcal nuclease (MNase) digestion to fractionate P4 and P30 brain chromatin (see Materials 
and Methods). It has been described that SI corresponds to a histone H1-depleted soluble fraction; the SE 
includes H1-containing mononucleosomes and nucleosome oligomers whereas the P fraction represents highly 
Figure 5. P-S164 MeCP2 shows a more dynamic binding to DNA. (a) Ribbon representation of the human 
MBD model in complex with a short DNA fragment. The residues of the Asx and ST structural motifs are 
reported in stick together with R162 and S164 residues that are not directly involved in the formation of the 
two motifs. MBD and DNA structures are colored in grey and orange, respectively. Asx and ST motifs are 
highlighted with a red dotted square. (b) As in panel a, with the addition of S164 phosphorylation. The black 
dashed arrow represents the electrostatic repulsion effect between the phosphate group of S164 and the DNA 
backbone. (c) Representation of the electrostatic potential mapped on the molecular surface of the MDB-DNA 
complex in the absence of phosphorylation. The red and blue colours represent the negatively and positively 
charged regions respectively. The black dashed circle underlines the C-terminal region that differs in the 
presence or absence of S164 phosphorylation. (d) As in c but in the presence of S164 phosphorylation.  
(e) Representative EMSAs showing binding of MeCP2 WT, S164A and S164D peptides to an unmethylated 
(upper panel), CpG methylated (middle panel) and CpA methylated (lower panel) probe.
www.nature.com/scientificreports/
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compacted chromatin resistant to MNase digestion29,30. As previously reported, we found that in adult brain most 
Mecp2 co-fractionates with SI. The same distribution is observed in P4 brains; P-S164 Mecp2 follows the overall 
protein distribution (Fig. 7a).
SI samples were fractionated on sucrose gradients to describe the distribution of P-S164 Mecp2 amid chro-
matin. Figure 7b shows that mononucleosomes peak between fractions 11–15 (upper panel). The western blot 
demonstrates that in adult brain the majority of total Mecp2 co-fractionates with mononucleosomes, although a 
fraction of the methyl-binding protein sediments with nucleosome-free DNA (fractions 17–23). P-S164 Mecp2 
shows a different profile with most of it co-sedimenting with free DNA. Importantly, in immature brain (P4), both 
total Mecp2 and its phospho-isoform show identical sedimentation profiles.
These data reinforce our results showing that the chromatin-binding properties of Mecp2 are extensively 
modified along brain maturation and that these changes are at least partially mediated by its differential phospho-
rylation. To confirm that phosphorylation of S164 significantly affects Mecp2 distribution among nucleosomes, 
the same assay was performed on 293T cells transfected with WT GFP-MeCP2 and its S164-mutated derivatives. 
The accumulation of all three exogenously expressed proteins in the SI fraction was confirmed (Fig. 7c). However, 
it is noticeable that the phospho-mimetic MeCP2 derivative is less represented in the insoluble P fraction, thus 
confirming its decreased affinity for chromatin. Sucrose gradient sedimentation of the SI fractions showed that 
a large fraction of the S164D derivative associates with nucleosome-free DNA, whereas the unphosphorylatable 
mutant mainly co-sediments with nucleosomes (Fig. 7d).
S164 phosphorylation controls nuclei dimension and dendritic patterning in vitro. We have pre-
viously demonstrated that Mecp2 affects nuclear size and neurite length in cultured neurons31. A role for S421 
Mecp2 phosphorylation in dendritic growth of primary neurons has also been established32. We exploited these 
Mecp2-related phenotypes to understand whether S164 phosphorylation is involved in neuronal maturation. 
Cultures were assayed at DIV7, when neuronal maturation is progressing and at DIV14, when functional syn-
apses are present33. Mecp2-null neurons were infected with lentiviruses expressing the WT or the mutated deriv-
atives of S164; the concomitant expression of GFP from the bicistronic cassette permitted to visualize neuronal 
morphology (Fig. 8). WT neurons infected with GFP expressing viruses were used as control. The expression 
of all derivatives was verified (Fig. S1), demonstrating that in mature neurons exogenously expressed MeCP2 is 
roughly 2.5 times more abundant than the endogenous protein.
By immunofluorescence we analyzed the subnuclear distribution of the exogenously expressed proteins. In 
line with mouse cerebral cortex34, although well-defined heterochromatic foci are present in DIV7 neurons, 
neither endogenous nor exogenous WT MeCP2 accumulates on them (Fig. 8a); the accumulation on pericen-
tromeric heterochromatic is instead well recognizable in more mature neurons (Fig. 8d). In accordance with 
previous publications24, at DIV14, MeCP2 overexpression causes heterochromatin clustering leading to larger 
and less numerous DAPI positive foci (Fig. 8d; KO+ WT). Importantly, the S164A derivative accumulates on 
heterochromatic foci already at DIV7, whereas the S164D derivative is diffused at both stages of neuronal matu-
ration. We confirmed that at DIV7 Mecp2-null neurons display smaller nuclei (Fig. 8c) and an evident reduction 
in the number of neurites longer than 80–100 μ m (Fig. 8b; for detailed measurements and statistical analyses 
see Fig. S2). WT and S164D derivatives normalized both the impaired dendritic branching and nuclear size. 
Conversely, neurons expressing the S164A mutant resembled the KO cells (8b,c). By repeating the analyses at 
DIV14, we found that Mecp2-null neurons have an exacerbated defect both in nuclear dimension (Fig. 8f) and 
dendritic branching (Fig. 8e). Neurons overexpressing WT MeCP2 show a dendritic phenotype that, although 
not reaching statistical significance, is normalized towards that of WT neurons. This result is in line with previous 
data suggesting that increased MeCP2 levels become more detrimental as maturation proceeds35. Overexpression 
of the S164D or S164A mutants did not show amelioration of the neuronal phenotypes. The capacity of the 
Figure 6. P-S164 MeCP2 represents a more soluble fraction of MeCP2 in brain. (a) Western blot showing 
salt extraction of MeCP2 and P-S164 MeCP2 with increasing concentrations of NaCl from P30 and P4 mouse 
brains (P30 n = 4, P4 n = 3). H1 was included as a control of the salt extraction. (b) Salt extraction of GFP-
MeCP2 and its S164A and S164D derivatives with increasing concentrations of NaCl from transfected NIH3T3 
cells (n = 3).
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phospho-mimetic mutant to normalize the morphological defects of immature but not mature Mecp2-null neu-
rons suggest that dephosphorylation of S164 is necessary to accomplish proper neuronal maturation. These 
experiments suggest the importance of the dynamic phosphorylation of S164, an event that is needed during 
early neuronal maturation but that must be dynamically regulated for terminal differentiation.
Discussion
Several biological processes have been linked to MeCP2 including activation and repression of transcription, 
regulation of global chromatin structure, control of alternative splicing and the biogenesis of non-coding 
RNAs2,3. Further, we demonstrated that MeCP2 affects protein synthesis36 and centrosomal functions10. These 
findings imply that MeCP2 is a multifunctional protein, whose numerous activities still need to be unraveled. 
The intrinsically disordered structure of MeCP2 and its several PTMs have been suggested to generate and reg-
ulate this functional versatility31,37. Several reports have proposed that differential phosphorylation of MeCP2 is 
a key mechanism by which the protein modulates its affinity for partners and/or DNA11,12. However, most of the 
MeCP2 PTMs studied so far involve almost exclusively the MBD/TRD regions of the protein and phosphoryla-
tion sites within the ID have never been characterized.
The ID consists of a short basic region with an amino acid composition similar to HMGA138. The high density 
of basic residues in the ID appears to positively influence the association of MeCP2 with the negatively charged 
DNA backbone. Indeed, FRAP analyses proved that the MBD is necessary and sufficient for targeting MeCP2 to 
heterochromatic foci, whereas the ID is crucial for its proper chromatin association. Deletion of the ID acceler-
ates the binding kinetics of MeCP2 without influencing its subnuclear localization23. In vitro, the ID and TRD 
contribute to the interaction of MeCP2 with DNA and nucleosomes39. It has thus been proposed that MeCP2 
Figure 7. P-S164 MeCP2 is not associated with mononucleosomes in brain. Brain and cell chromatin was 
subjected to MNase digestion to obtain SI, SE and P chromatin fractions. SI contains histone H1-depleted 
mononucleosomes; the SE includes H1-containing mononucleosomes and poly-nucleosomes whereas the P 
fraction represents chromatin resistant to MNase digestion. (a,b) Western blots of nuclear MeCP2, P-S164 
MeCP2 and H4 partitioning in the SI, SE and P fractions obtained from digested P4 and P30 brain chromatin 
(a). Sucrose gradient fractionation of the SI chromatin fractions (b). The graph depicts the DNA absorbance 
(260 nm) profile of the numbered fractions collected along the gradient. The lower panel shows the western blot 
analysis using MeCP2 and P-S164 MeCP2 antibodies. (c,d) Western blots of nuclear WT GFP-MeCP2, S164A 
and S164D partitioning in the SI, SE and P chromatin fractions of transfected HEK293T cells (c). Sucrose 
gradient fractionation of the SI chromatin fractions (d). The lower panel shows the western blot analysis using 
GFP antibody.
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organizes chromatin structure through homo- and hetero associations, largely mediated by its ID and TRD40. The 
relevance of the ID is further highlighted by the recent identification of two missense mutations (p.Gly185Val 
and p.Arg167Trp) in families affected by intellectual disability19. Missense mutations in the ID are inherited 
Figure 8. A dynamic phosphorylation of MeCP2 at S 164 is necessary to ensure proper neuronal dendritic 
branching and nuclear size. (a,d) Representative images from DIV7 (a) and DIV 14 (d) neurons prepared from 
WT or Mecp2 KO E15 cortices. For each condition, under the GFP panel, the three squares show magnification 
of nuclei stained respectively with: MeCP2 (left), DAPI (centre); merged image is on the right. KO neurons 
were infected at 0 DIV with MeCP2 WT (KO+ WT) or the S164A (KO+ S164A) and S164D (KO+ S164D) 
derivatives. (b,e) Quantification of dendritic branch complexity by Sholl analysis at DIV7 (b) and 14 (e) (data 
are presented as mean ± SEM) (See Supplementary information Fig. S2 for statistical analyses).  
(c,f) Quantification of nuclear diameter at DIV7 (c) and 14 (f) (data are represented as mean ± SEM,  
* p = < 0.05, * * p = < 0.01, * * * p = < 0.001, * * * * p = < 0.0001, one way ANOVA) (three animals per genotype at 
least 20 neurons per condition).
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from asymptomatic mothers with skewed X-chromosome inactivation; in males they cause intellectual disability 
and not encephalopathy or RTT19,41. We emphasize that these MECP2 alterations either do not appear in the 
RettBase syndrome database (http://mecp2.chw.edu.au; p.Gly185Val) or are still reported as of uncertain sig-
nificance. Interestingly, the database reports five additional pathogenic mutations (P172; P173; P179; A181 and 
P199) affecting the ID region.
Considering all above and the fact that S164 was the only ID residue found phosphorylated in rodent brain20, 
we used in silico modeling to add structural information useful to understand the impact of S164 phosphorylation 
on MeCP2 binding to DNA. As reported by the X-ray structure, the C-terminal region of the MBD has a crucial 
role in the interaction with DNA25. S164 phosphorylation is expected to have two main effects on the adjacent 
MBD: a destabilization of the structure of the Asx and ST motifs (mediated by an electrostatic interaction with 
R162) and a lower affinity of the MBD for DNA, independently on its epigenetic modifications, caused by the 
addition of a negative charge at the interaction surface.
The in silico predictions have been confirmed by our EMSAs. Indeed, the polypeptide carrying the S164D 
mutation shifts the DNA probes but forms diffused bands, indicating that the S164D-polypeptide/DNA complex 
is unstable under these electrophoretic conditions. Expression of the full-length MeCP2 derivatives in cells con-
firms that the phospho-mimetic mutant is characterized by a more dynamic binding both to euchromatin and 
heterochromatin, whereas the phospho-defective derivative has a slightly but significantly increased affinity for 
chromatin. Accordingly, in adult brain, P-S164 Mecp2 dissociates from chromatin at lower ionic strength than 
global Mecp2, highlighting the impact of this PTM on the affinity of MeCP2 for DNA.
Skene et al. demonstrated that Mecp2 is globally bound to the genome in mature neurons, tracking the pres-
ence of methylated nucleotides5. The authors argued that, in neurons, MeCP2 functions as a chromatin architec-
tural factor dampening transcriptional noise genome-wide, thus rendering the identification of MeCP2 direct 
targets less relevant. It was suggested that MeCP2 phosphorylation might transiently relieve this global repression 
and facilitate appropriate gene expression. However, ChIP-seq approaches and/or immunofluorescence experi-
ments used to describe the genomic distribution and/or intracellular localization of specific phospho-isoforms 
of MeCP2 (P-S421, P-S424, P-S80, P-T308, P-S229)12 failed in revealing a global detachment of P-Mecp2 from 
chromatin. S164 phosphorylation appears to be the first described event of MeCP2 phosphorylation capable of 
globally affecting its binding to chromatin. This PTM occurs mainly in maturing brains and neurons rather than 
in mature cells. Importantly, our salt extraction analyses demonstrate that in perinatal brains, when Mecp2 is 
highly phosphorylated on S164, the methyl-binding protein is also less tightly bound to chromatin. Given the 
consistency of these data with the overexpression of MeCP2 S164 derivatives in cells, we suggest that the activity 
of P-S164 MeCP2 is not influenced by its abundance.
Here we report for the first time a phosphorylation event of MeCP2 depending on neuronal development. 
Moreover, our results provide the first demonstration that the affinity of MeCP2 binding to nucleosomes is signif-
icantly influenced by brain maturation reinforcing the novel notion that MeCP2 functions are developmentally 
regulated. We speculate that, similarly to histones42, such regulation is mainly achieved through differential PTMs 
that altogether generate an MeCP2 code with its counterpart of writer, reader and eraser multiprotein complexes.
Genome-wide chromatin immunoprecipitations have been used to identify whether MeCP2 
phospho-isoforms or-derivatives differ in their genomic distribution. No changes have been reported so far15. 
These results might reflect the technical constraints of this approach. Indeed, since MeCP2 is globally bound to 
the genome, in these types of analyses it is certainly difficult to achieve the necessary sequencing depth to prop-
erly quantify any local change. Further, the time of formaldehyde crosslinking affects the capability to capture 
transient MeCP2-DNA interactions and the field is still missing a gold standard protocol. Considering all above, 
and the caveat that S164 phosphorylation alters the dynamics of MeCP2 binding to chromatin, we decided to not 
carry out these studies at present.
When the expression of WT MeCP2 or its phospho-derivatives in Mecp2-null primary neurons was used to 
study the relevance of S164 phosphorylation, we found that the WT and S164D derivative, but not the S164A 
mutant, have the capacity to normalize both the nuclear diameter and dendritic arborization in young neurons. 
This indicates that the mere ability of MeCP2 to bind DNA is not sufficient to rescue phenotypes caused by the 
lack of the protein and that proper MeCP2 regulation through PTMs plays a crucial role during neuronal develop-
ment. In mature neurons, we did not observe any rescue with the phospho-mimetic or -defective derivatives. By 
analyzing overt morphological phenotypes at two different DIVs, we demonstrated that the detrimental effects of 
MeCP2 overexpression worsen with neuronal maturation, suggesting the need of testing the functional relevance 
of MeCP2 mutants in immature primary neurons.
To conclude, our data highlight S164 phosphorylation as a developmentally regulated PTM of MeCP2 with a 
relevant impact on its DNA/chromatin binding properties. Further, they provide support to the hypothesis that 
MeCP2 PTMs might integrate different signals, which finally lead to adaptive structural and/or transcriptional 
outputs.
To date, no pathologic mutation has been reported at this site. As a possible explanation, we can assume that 
additional PTMs synergistically occur with S164 phosphorylation to develop a full functional outcome. This 
hypothesis fits well with the demonstration that in mouse brain MeCP2 poly(ADP-ribosyl)ation decreases DNA 
binding affinity and chromatin clustering18. Importantly, the main region affected by this PTM was narrowed 
down to amino acids 106–203. It is also possible that by extending the cohorts of patients screened in molecular 
testing to include mild neurological symptoms, pathological mutations at S164 will be identified.
Materials and Methods
Plasmids. Amplified hMeCP2E1 was cloned into the BamHI site of pEGFPC1 (Clontech). MeCP2-S164A/D 
mutants were obtained by site directed mutagenesis using the QuickChange XL Site-Directed Mutagenesis Kit 
(Stratagene). MeCP2 fragments (aa 74–172) were PCR amplified from the pEGFPC1-MeCP2 derivatives (WT, 
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S164A/D) and cloned into pTYB1 vector (NEB). The pLLiGFP was obtained by cloning the iresGFP cassette from 
pCAGGSiGFP plasmid into pLL3.7 hMeCP2E1 WT, S164A/D were cloned into the BamHI site of the pLLiGFP 
vector.
All constructs were verified by sequencing.
Animals. The Mecp2-null mouse strain, originally purchased from Jackson Laboratories (003890 
B6.129P2(C)-Mecp2< tm1.1Bird> /J), was maintained on a CD1 background and genotyped as described in31. 
Animals were kept in our on site animal room and routinely checked for general health conditions. All proce-
dures were performed in accordance with the European Community Council Directive 86/609/EEC for care and 
use of experimental animals; protocols were approved by the Italian Minister for Scientific Research and by the 
San Raffaele Scientific Institutional Animal Care and Use Committee in accordance with the Italian law.
Generation of phospho-specific antibodies. The anti-MeCP2 S164 phospho-site specific antibody was 
generated by Diagenode, Inc. Rabbits were immunized with the peptide [NH2]-TGRG-pS-PSRRE-[COOH]. The 
antibody was purified by Covance, Inc, passing the antiserum on a column containing the non-phosphorylated 
peptide and applying the flow-through to a second column that was conjugated to the phosphorylated peptide.
Cell culture and transfection. HEK293T and NIH3T3 cells were maintained in DMEM (Sigma-Aldrich) 
supplemented with 10% FBS, L-glutamine, 100 units/ml penicillin, and 100 μ g/ml streptomycin. MEF cultures 
from WT and Mecp2-null mice were prepared from E14 as described in10.
Cells were plated and transfected exploiting LipofectamineTM 2000 (Life Tech.) or with the calcium phosphate 
method. Cells were collected or fixed 24 hour post-transfection.
Immunofluorescence. MEF and NIH3T3 cells were fixed with 4% PFA for 20 min at RT, permeabilized and 
blocked for 1 h with 5% Horse serum, 0.2% Triton-X-100 in TBS. An anti GFP antibody (Roche 11814460001, 
1:1000) was added overnight (4 °C). Slides were incubated with the secondary antibody (Anti mouse Alexa Fluor 
488) for 1 h at RT and washed. DNA was counter stained with DAPI (Life Tech.). Slides were mounted with 
ProLong Gold Antifade Reagent (Life Tech.). Images were acquired with a NikonEclipse Ni upright microscope. 
All images were acquired with identical settings for exposure time. Analysis of fluorescence at chromocenters and 
in the nucleoplasm was performed using ImageJ (NIH) threshold tool.
Primary neuronal cultures. Primary neuronal cultures were prepared from mouse embryo brains of either 
E15 or E17 as described in31. Neurons were cultured in Neurobasal medium (Invitrogen) supplemented with 
2% B27 (Invitrogen) and glutamine (Sigma Aldrich). 1 × 104 hippocampal neurons were plated on coverslips in 
24-well plates and 1 × 105 cortical neurons in 6-well plates, both coated with poly-L-lysine.
Lentiviral production. HEK293T cells were cotransfected with the packaging vectors pVSV-G, pMDL, 
pREV and either pll3.7iGFP or pll3.7 hMeCP2iGFP, pll3.7 hMeCP2S164AiGFP and pll3.7 hMeCP2S164DiGFP 
using CaCl2 transfection protocol. Viral particles were harvested 36 h post-transfection and concentrated 250-fold 
by ultracentrifugation43. Viruses were resuspended in PBS and stored at − 80 °C. Viral titers were typically 
3–6 × 106 pfu/μ l. Neurons were infected with lentiviruses at a final concentration of 2.5 × 1 06 pfu/ml for 6 well 
plates and 2.5 × 105 pfu/ml for 24 well plates at 0–1 DIV. To enhance GFP expression, neurons used for morpho-
logical analyses were coinfected with lentiviruses encoding GFP.
Morphological analysis. Morphological analyses were performed on cortical neurons, DIV7 and 14. 
Immunofluorescence was performed as described using antibodies against GFP, MeCP2 (Sigma M9317, 1:200) 
and DAPI. Sholl analysis was performed using the dedicated plugin of ImageJ. Size of neuronal nuclei was evalu-
ated with ImageJ by measuring the DAPI-stained area of each nucleus.
Protein extraction and western blotting. Mouse tissues and transfected cells were homogenized in 
lysis buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM DTT) supplemented 
with PhosSTOP (Roche), cOmplete EDTA-free protease inhibitor cocktail (Roche) with a dounce homogenizer. 
Homogenates were centrifuged at maximum speed at 4 °C for 15 minutes, and the supernatant collected.
Proteins were separated on either a 8 or 10% SDS-PAGE and transferred to nitrocellulose membrane. 
Membranes were blocked in TBST (10 mM Tris–HCl, pH 8.0, 150 mM NaCl and 0.05% Tween-20) contain-
ing 5% milk and incubated with primary antibodies overnight at 4 °C. The following primary antibodies were 
used: MeCP2 (Sigma M9317, 1:1000), pS164-MeCP2 (1:1000), Tuj-1 (Sigma T2200, 1:10.000), GFP (Roche 
11814460001, 1:1000), H1 (GeneTex GTX87506, 1:1000), and H4 (made in house29, 1:10.000). After washing 
filters were incubated with appropriate secondary antibody (Life Technologies) for 1 hour at RT. Detection was 
performed by enhanced chemiluminescence (EuroClone). For quantitative measurements, autoradiographs were 
acquired using a G-box Chemi XX6 (Syngene) or scanned. Image analysis was performed with ImageJ (NIH).
Chromatin fractionation. Brains and transfected cells were homogenized in buffer A (0.25 M sucrose, 
60 mM KCl, 15 mM NaCl, 10 mM MES pH 6.5, 5 mM MgCl2, 0.5% Triton and PhosSTOP (Roche), cOmplete 
EDTA-free protease inhibitor cocktail (Roche) and incubated for 10 minutes on ice. Nuclei were collected by 
centrifugation at 4500 xg for 10 minutes (4 °C). Isolated nuclei were resuspended in buffer B (50 mM NaCl, 10 mM 
PIPES pH 6.8, 5 mM MgCl2, 1 mM CaCl2) to a final concentration of 2 mg/ml at A260. Nuclei were digested using 
MNase (Worthington) at a concentration of 30 U/mg of DNA at 37 °C for 15 minutes. Reactions were stopped by 
adding EDTA to a final concentration of 20 mM on ice. Digested nuclei were immediately centrifuged at 9000 xg 
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for 10 min at 4 °C to collect S1 supernatant fraction. The remaining pellet was lysed in 0.25 mM EDTA with stir-
ring for 1 hour (4 °C). After centrifugation at 16.000 xg for 10 minutes at 4 °C, the supernatant SE and an insoluble 
lysis-resistant pellet (P) were produced.
Sucrose gradient fractionation. The SI supernatant was fractionated on a 5–20% sucrose gradient in 
25  mM NaCl, 10  mM Tris pH 7.5 and 5  mM EDTA buffer at 96.000 xg for 21 hours (4 °C) using a Beckman 
L8–70 M ultracentrifuge and a SW28 swing rotor with no deceleration. 0.5 ml fractions were collected and sub-
jected to western blotting to determine the presence of phosphorylated and total MeCP2.
Salt extraction. Brains and transfected cells were lysed in 10 mM Hepes pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 
0.2% NP40, 0,1 mM EDTA, 10% glycerol, PhosSTOP (Roche), cOmplete EDTA-free protease inhibitor cocktail 
(Roche), on ice, using a potter homogenizer. Samples were incubated 30 min on ice and centrifuged at 2000 xg for 
5 min at 4 °C. Nuclear pellets were resuspended in 10 mM Tris pH 7.4, PhosSTOP, cOmplete EDTA-free protease 
inhibitor cocktail supplemented with 200 mM NaCl. Samples were vortexed and incubated on ice for 20  min, 
followed by centrifugation at 2000xg for 5 min. Supernatants were collected. The same procedure was repeated 
for other 5 times, supplementing each time the sample with the same buffer but containing an increased amount 
of NaCl corresponding to 300, 400, 500, 600 and 700 mM. For western blotting analysis, equal volume of each 
fraction was loaded on a 10% acrylamide gel.
Fluorescence recovery after photobleaching. GFP-MeCP2 WT, GFP-MeCP2 S164A and GFP-MeCP2 
S164D plasmids were transiently transfected in NIH3T3 cells with Lipofectamine 2000 (Life Technologies). 
Twenty hours post-transfection cells were analyzed as described in21.
Recombinant MeCP2 purification. An overnight pre-culture of ER2566 cells transformed with a 
MeCP2(74–172)TYB1 plasmid was diluted 100 times in LB (100 μ g/ml ampicillin) and allowed to grow at 37 °C 
up to 0.6–0.8 OD at 595 nm. IPTG (1mM) induction was performed at 30 °C for 5 hours. Bacteria were col-
lected and lysed in lysis buffer (750 mM NaCl, 20 mM Tris-HCl pH 8, 1 mM EDTA pH 8, 0.1% Triton X100) 
followed by sonication (15 min 100% amplitude). Supernatant lysates were collected by centrifugation and passed 
5 times through a chitin resin (NEB) column. Proteins were eluted by incubating over night at 4 °C the columns in 
lysis buffer containing 50 mM DTT, and collecting fractions of 200 μ l. Eluted polypeptides were dialyzed against 
20 mM Hepes, 100 mM NaCl, 10% Glycerol, 0.250 mM EDTA pH 8 and quantified using BCA assay.
Electrophoretic mobility shift assay. Oligonucleotides probes either unmethylated or containing one 
methyl CA or a symmetrically methylated CG were annealed by boiling reverse and forward strands at 95 °C for 
5 min and then cooling down for at least 4 hours. Sequences were as follows26:
Forward 5′ - CTAAAGGAAAAGTGACGCACTGTTTTACACCTTGGTTTT-3′ 
Reverse 5′ - AAAACCAAGGTGTAAAACAGTGCGTCACTTTTCCTTTAG-3′ 
Bold C refers to methylated residues.
Increasing amounts of MeCP2 recombinant protein (0, 125, 250, 500 ng) were incubated with 0.1 mg/ml BSA 
and 200 ng of annealed probe in EMSA buffer (10 mM Tris HCl, 50 mM KCl, 0.5 mM MgCl2, 0.1 mM EDTA, 5% 
glycerol) at RT for 30 min. Samples were loaded on a 6% acrylamide gel in 1X TAE. Electrophoresis was devel-
oped at 100 V for 1 h. Gels were stained with ethidium bromide.
In silico molecular modeling. The crystal structure of the hMeCP2 MBD in complex with a methylated 
DNA sequence from BDNF (PDB ID 3C2I)25 has been used as starting structure to model the C-terminal region 
of the MBD. The last 8 residues (Gly163 to Gln170) were modeled using the I-Tasser web server44 while phos-
phorylation was added using the Sybyl software (www.tripos.com). The structure of both models was regularized 
using 10.000 steps of the energy minimization protocol applying the steepest descents algorithm. The energy 
minimization was performed using the AMBER14 software.
The PBEQ-Solver web server45 was used for the calculation of the electrostatic potential. The structures 
obtained after energy minimization were submitted to the server for calculations.
Figures were obtained using UCSF Chimera v. 1.10.146.
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